Last reviewed · How we verify
NCT02753790
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
NA trial testing Intensity Modulated Radiotherapy in Neoplasm Metastasis in 29 participants. Completed in 10 April 2022.
22 April 2021
Quick facts
| Lead sponsor | New Mexico Cancer Research Alliance |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 9 March 2016 |
| Primary completion | 22 April 2021 |
| Estimated completion | 10 April 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intensity Modulated Radiotherapy
Conditions studied
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Central Nervous System Metastases — all drugs for Central Nervous System Metastases →
Sponsor
New Mexico Cancer Research Alliance — full company profile →
Who can join
18 and older, any sex, with Neoplasm Metastasis or Central Nervous System Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Some cancers can spread, or metastasize, to the brain. When they do, treatment often involves surgery and/or radiation. Optimal treatment of brain metastases would maximize disease control and minimize toxicity (or side effects), and improve the quality of life of patients. A common type of radiation used for brain metastases is called whole brain radiation, which treats not just the cancer that can be seen on scans (i.e., gross disease), but the smaller sites of cancer that may not be visible (i.e. subclinical disease). Fractionation is used to describe repetitive treatments in which small doses (fractions) of a total planned dose are given at separate clinic visits. The most common dosing regimen is 30 Gray (Gy), using 3 Gy per fraction over 10 fractions. Previous studies have suggested that using intensity modulated radiation therapy (IMRT) may be a safer way to deliver higher doses to gross disease and lower doses to the rest of the brain that may contain subclinical disease. This approach may spare the rest of the brain from radiation complications and side effects. The goal of this study is to determine whether using IMRT to treat brain metastases is more effective than current standard whole brain radiation in controlling gross disease and whether patient quality of life and hair loss is improved compared to previous studies using whole brain radiation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02753790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intensity Modulated Radiotherapy
Trials testing the same drug.
- NCT06546267 — Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART) · recruiting
- NCT02201355 — Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck · Phase 1 · terminated
Other recruiting trials for Neoplasm Metastasis
Currently open trials in the same condition.
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
- NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
- NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
- NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting
Other New Mexico Cancer Research Alliance trials
Trials by the same sponsor.
- NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial · Phase 2 · not yet recruiting
- NCT06260332 — Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors · NA · active not recruiting
- NCT06207864 — Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing · NA · recruiting
- NCT05176743 — Food Insecurity in Oncology · NA · completed
- NCT04259762 — Enhancing Cancer Prevention and Control Pathways-Native Health Initiative · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02753790 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New Mexico Cancer Research Alliance
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02753790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing